<?xml version='1.0' encoding='utf-8'?>
<document id="21631929"><sentence text="No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study."><entity charOffset="68-79" id="DDI-PubMed.21631929.s1.e0" text="roflumilast" /><entity charOffset="92-102" id="DDI-PubMed.21631929.s1.e1" text="formoterol" /><pair ddi="false" e1="DDI-PubMed.21631929.s1.e0" e2="DDI-PubMed.21631929.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21631929.s1.e0" e2="DDI-PubMed.21631929.s1.e1" /></sentence><sentence text="Roflumilast is an oral, selective phosphodiesterase 4 inhibitor with anti-inflammatory effects in chronic obstructive pulmonary disease (COPD)"><entity charOffset="0-11" id="DDI-PubMed.21631929.s2.e0" text="Roflumilast" /></sentence><sentence text=" The addition of roflumilast to long-acting bronchodilators improves lung function in patients with moderate-to-severe COPD"><entity charOffset="17-28" id="DDI-PubMed.21631929.s3.e0" text="roflumilast" /></sentence><sentence text=" The present study investigated drug-drug interaction effects between inhaled formoterol and oral roflumilast"><entity charOffset="78-88" id="DDI-PubMed.21631929.s4.e0" text="formoterol" /><entity charOffset="98-109" id="DDI-PubMed.21631929.s4.e1" text="roflumilast" /><pair ddi="false" e1="DDI-PubMed.21631929.s4.e0" e2="DDI-PubMed.21631929.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21631929.s4.e0" e2="DDI-PubMed.21631929.s4.e1" /></sentence><sentence text="" /><sentence text="This was a single-centre (investigational clinic), open, randomised, multiple-dose, parallel-group study" /><sentence text=" In Regimen A, healthy men were treated with roflumilast (500 μg tablet once daily; Day 2-18) and concomitant formoterol (24 μg twice daily; Day 12-18)"><entity charOffset="45-56" id="DDI-PubMed.21631929.s7.e0" text="roflumilast" /><entity charOffset="110-120" id="DDI-PubMed.21631929.s7.e1" text="formoterol" /><pair ddi="false" e1="DDI-PubMed.21631929.s7.e0" e2="DDI-PubMed.21631929.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21631929.s7.e0" e2="DDI-PubMed.21631929.s7.e1" /></sentence><sentence text=" In Regimen B, healthy men were treated with formoterol (24 μg twice daily; Day 2-18) and concomitant roflumilast (500 μg once daily; Day 9-18)"><entity charOffset="45-55" id="DDI-PubMed.21631929.s8.e0" text="formoterol" /><entity charOffset="102-113" id="DDI-PubMed.21631929.s8.e1" text="roflumilast" /><pair ddi="false" e1="DDI-PubMed.21631929.s8.e0" e2="DDI-PubMed.21631929.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21631929.s8.e0" e2="DDI-PubMed.21631929.s8.e1" /></sentence><sentence text=" Steady-state plasma pharmacokinetics of roflumilast, roflumilast N-oxide and/or formoterol (Cmax and AUC0-τ) as well as pharmacodynamics - blood pressure, transthoracic impedance cardiography (ZCG), 12-lead digital electrocardiography, peripheral blood eosinophils, and serum glucose and potassium concentrations - were evaluated through Day 1 (baseline), Day 8 (Regimen B: formoterol alone) or Day 11 (Regimen A: roflumilast alone), and Day 18 (Regimen A and B: roflumilast plus formoterol)"><entity charOffset="41-52" id="DDI-PubMed.21631929.s9.e0" text="roflumilast" /><entity charOffset="54-73" id="DDI-PubMed.21631929.s9.e1" text="roflumilast N-oxide" /><entity charOffset="81-91" id="DDI-PubMed.21631929.s9.e2" text="formoterol" /><entity charOffset="102-108" id="DDI-PubMed.21631929.s9.e3" text="AUC0-τ" /><entity charOffset="277-284" id="DDI-PubMed.21631929.s9.e4" text="glucose" /><entity charOffset="289-298" id="DDI-PubMed.21631929.s9.e5" text="potassium" /><entity charOffset="375-385" id="DDI-PubMed.21631929.s9.e6" text="formoterol" /><entity charOffset="415-426" id="DDI-PubMed.21631929.s9.e7" text="roflumilast" /><entity charOffset="464-475" id="DDI-PubMed.21631929.s9.e8" text="roflumilast" /><entity charOffset="481-491" id="DDI-PubMed.21631929.s9.e9" text="formoterol" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e0" e2="DDI-PubMed.21631929.s9.e9" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e1" e2="DDI-PubMed.21631929.s9.e9" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e2" e2="DDI-PubMed.21631929.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e2" e2="DDI-PubMed.21631929.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e2" e2="DDI-PubMed.21631929.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e2" e2="DDI-PubMed.21631929.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e2" e2="DDI-PubMed.21631929.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e2" e2="DDI-PubMed.21631929.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e2" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e2" e2="DDI-PubMed.21631929.s9.e9" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e3" e2="DDI-PubMed.21631929.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e3" e2="DDI-PubMed.21631929.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e3" e2="DDI-PubMed.21631929.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e3" e2="DDI-PubMed.21631929.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e3" e2="DDI-PubMed.21631929.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e3" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e3" e2="DDI-PubMed.21631929.s9.e9" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e4" e2="DDI-PubMed.21631929.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e4" e2="DDI-PubMed.21631929.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e4" e2="DDI-PubMed.21631929.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e4" e2="DDI-PubMed.21631929.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e4" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e4" e2="DDI-PubMed.21631929.s9.e9" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e5" e2="DDI-PubMed.21631929.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e5" e2="DDI-PubMed.21631929.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e5" e2="DDI-PubMed.21631929.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e5" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e5" e2="DDI-PubMed.21631929.s9.e9" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e6" e2="DDI-PubMed.21631929.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e6" e2="DDI-PubMed.21631929.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e6" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e6" e2="DDI-PubMed.21631929.s9.e9" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e7" e2="DDI-PubMed.21631929.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e7" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e7" e2="DDI-PubMed.21631929.s9.e9" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e8" e2="DDI-PubMed.21631929.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21631929.s9.e8" e2="DDI-PubMed.21631929.s9.e9" /></sentence><sentence text=" Blood and urine samples were taken for safety assessment at screening, pharmacokinetic profiling days and Day 19" /><sentence text=" Adverse events were monitored throughout the study" /><sentence text="" /><sentence text="Of the 27 subjects enrolled, 24 were evaluable (12 in each regimen)" /><sentence text=" No relevant pharmacokinetic interactions occurred" /><sentence text=" Neither roflumilast nor formoterol were associated with significant changes in cardiovascular parameters as measured by ZCG, and these parameters were not affected during concomitant administration"><entity charOffset="25-35" id="DDI-PubMed.21631929.s15.e0" text="formoterol" /></sentence><sentence text=" Formoterol was associated with a slight increase in heart rate and a corresponding shortening of the QT interval, without changes in the heart rate-corrected QTc interval"><entity charOffset="1-11" id="DDI-PubMed.21631929.s16.e0" text="Formoterol" /></sentence><sentence text=" There were small effects on the other pharmacodynamic assessments when roflumilast and formoterol were administered individually, but no interactions or safety concerns were seen after concomitant administration"><entity charOffset="72-83" id="DDI-PubMed.21631929.s17.e0" text="roflumilast" /><entity charOffset="88-98" id="DDI-PubMed.21631929.s17.e1" text="formoterol" /><pair ddi="false" e1="DDI-PubMed.21631929.s17.e0" e2="DDI-PubMed.21631929.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21631929.s17.e0" e2="DDI-PubMed.21631929.s17.e1" /></sentence><sentence text=" No severe or serious adverse events were reported, and no adverse events led to premature study discontinuation" /><sentence text="" /><sentence text="No clinically relevant pharmacokinetic or pharmacodynamic interactions were found when oral roflumilast was administered concomitantly with inhaled formoterol, including no effect on cardiac repolarisation"><entity charOffset="92-103" id="DDI-PubMed.21631929.s20.e0" text="roflumilast" /><entity charOffset="148-158" id="DDI-PubMed.21631929.s20.e1" text="formoterol" /><pair ddi="false" e1="DDI-PubMed.21631929.s20.e0" e2="DDI-PubMed.21631929.s20.e0" /><pair ddi="false" e1="DDI-PubMed.21631929.s20.e0" e2="DDI-PubMed.21631929.s20.e1" /></sentence><sentence text=" Roflumilast was well tolerated"><entity charOffset="1-12" id="DDI-PubMed.21631929.s21.e0" text="Roflumilast" /></sentence><sentence text="" /></document>